The effect of glucagon-like peptide 1 on cardiovascular risk

Nature Reviews Cardiology

Volumn 9, Issue 4, 2012, Pages 209-222

  Sivertsen, Jacob ^a   Rosenmeier, Jaya ^a   Holst, Jens J ^b   Vilsbøll, Tina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADX 91886; ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLYMERA; INSULIN; INSULIN GLARGINE; ITCA 650; LIRAGLUTIDE; LIXISENATIDE; LX 4211; LY 2428757; MAR 701; METFORMIN; NN 9924; ORMD 0901; PC DAC; PF 04603629; SEMAGLUTIDE; SULFONYLUREA; TASPOGLUTIDE; TTP 054; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VRS 859; ZP 2929;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; ENZYME ACTIVATION; GLUCOSE METABOLISM; HALF LIFE TIME; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RATE; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; IN VITRO STUDY; INFLAMMATION; LIPID METABOLISM; META ANALYSIS (TOPIC); MICROANGIOPATHY; MORBIDITY; MORTALITY; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STROKE; SYSTOLIC BLOOD PRESSURE; TISSUE DISTRIBUTION; TREATMENT DURATION; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859103180     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.211     Document Type: Review

References (135)

1. International Diabetes Federation. IDF Diabetes Atlas 4th edn (International Diabetes Federation, Brussels, 2009).
2. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004). (Pubitemid 38579764)
3. Mata-Cases, M. et al. Incidence of complications and mortality in a type 2 diabetes patient cohort study followed up from diagnosis in a primary healthcare center. Int. J. Clin. Pract. 65, 299-307 (2011).
4. Haffner, S. M., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339, 229-234 (1998). (Pubitemid 28350165)
5. Juutilainen, A., Lehto, S., Ronnemaa, T., Pyorala, K. & Laakso, M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28, 2901-2907 (2005). (Pubitemid 43942922)
6. Nauck, M. A. et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C peptide responses. J. Clin. Endocrinol. Metab. 63, 492-498 (1986). (Pubitemid 16035703)
7. Holst, J. J. The physiology of glucagon-like peptide 1. Physiol. Rev. 87, 1409-1439 (2007). (Pubitemid 350041474)
8. Holst, J. J., Madsbad, S. & Schmitz, O. in Textbook of Diabetes 4th edn (eds Holt, R. I. G., Cockram, C. S., Flyvbjerg, A & Goldstein, B) 478-493 (Wiley-Blackwell Publishing, New Jersey, (2010).
9. Deacon, C. F. et al. Dipeptidyl peptidase IV resistant analogs of glucagon-like peptide 1 which have extended metabolic stability and improved biological activity. Diabetologia 41, 271-278 (1998). (Pubitemid 28254820)
10. Deacon, C. F. et al. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44, 1126-1131 (1995).
11. Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L. & Yellon, D. M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54, 146-151 (2005). (Pubitemid 40105106)
12. Nauck, M. A. et al. Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation. Acta Diabetol. 30, 39-45 (1993). (Pubitemid 23286367)
13. Vilsbøll, T., Krarup, T., Madsbad, S. & Holst, J. J. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45, 1111-1119 (2002). (Pubitemid 34985287)
14. Vilsbøll, T., Agersø, H., Krarup, T. & Holst, J. J. Similar elimination rates of glucagon-like peptide 1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88, 220-224 (2003). (Pubitemid 36115169)
15. Mayo, K. E. et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55, 167-194 (2003). (Pubitemid 36268402)
16. Fehmann, H. C. et al. Ligand-specificity of the rat GLP I receptor recombinantly expressed in Chinese hamster ovary (CHO ) cells. Z. Gastroenterol. 32, 203-207 (1994).
17. Alvarez, E. et al. The expression of GLP 1 receptor mRNA and protein allows the effect of GLP 1 on glucose metabolism in the human hypothalamus and brainstem. J. Neurochem. 92, 798-806 (2005). (Pubitemid 40229551)
18. Ban, K. et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117, 2340-2350 (2008). (Pubitemid 351653542)
19. Bullock, B. P., Heller, R. S. & Habener, J. F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide 1 receptor. Endocrinology 137, 2968-2978 (1996). (Pubitemid 26192194)
20. Campos, R. V., Lee, Y. C. & Drucker, D. J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide 1 in the mouse. Endocrinology 134, 2156-2164 (1994). (Pubitemid 24142957)
21. Egan, J. M., Montrose-Rafizadeh, C., Wang, Y., Bernier, M. & Roth, J. Glucagon-like peptide 1(7-36) amide (GLP 1) enhances insulin-stimulated glucose metabolism in 3T3 L1 adipocytes: one of several potential extrapancreatic sites of GLP 1 action. Endocrinology 135, 2070-2075 (1994). (Pubitemid 24363904)
22. Kanse, S. M., Kreymann, B., Ghatei, M. A. & Bloom, S. R. Identification and characterization of glucagon-like peptide 1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett. 241, 209-212 (1988). (Pubitemid 19005008)
23. Korner, M., Stockli, M., Waser, B. & Reubi, J. C. GLP 1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J. Nucl. Med. 48, 736-743 (2007). (Pubitemid 47604973)
24. Lankat-Buttgereit, B., Goke, R., Fehmann, H. C., Richter, G. & Goke, B. Molecular cloning of a cDNA encoding for the GLP 1 receptor expressed in rat lung. Exp. Clin. Endocrinol. 102, 341-347 (1994).
25. Larsen, P. J., Tang-Christensen, M., Holst, J. J. & Orskov, C. Distribution of glucagon-like peptide 1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77, 257-270 (1997). (Pubitemid 27060323)
26. Merchenthaler, I., Lane, M. & Shughrue, P. Distribution of pre pro glucagon and glucagon-like peptide 1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol. 403, 261-280 (1999). (Pubitemid 28566834)
27. Orskov, C. & Poulsen, S. S. Glucagonlike peptide I (7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 40, 1292-1296 (1991).
28. Richter, G. et al. GLP 1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am. J. Physiol. 265, L374-L381 (1993).
29. Satoh, F. et al. Characterization of human and rat glucagon-like peptide 1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology 141, 1301-1309 (2000). (Pubitemid 32269096)
30. Shimizu, I., Hirota, M., Ohboshi, C. & Shima, K. Identification and localization of glucagon-like peptide 1 and its receptor in rat brain. Endocrinology 121, 1076-1082 (1987). (Pubitemid 17139162)
31. Uttenthal, L. O. & Blazquez, E. Characterization of high-affinity receptors for truncated glucagon-like peptide 1 in rat gastric glands. FEBS Lett. 262, 139-141 (1990). (Pubitemid 20104280)
32. Uttenthal, L. O., Toledano, A. & Blazquez, E. Autoradiographic localization of receptors for glucagon-like peptide 1 (7-36) amide in rat brain. Neuropeptides 21, 143-146 (1992).
33. Wei, Y. & Mojsov, S. Tissue-specific expression of the human receptor for glucagon-like peptide I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358, 219-224 (1995).
34. Arnes, L., Moreno, P., Nuche-Berenguer, B., Valverde, I. & Villanueva-Penacarrillo, M. L. Effect of exendin 4 treatment upon glucose uptake parameters in rat liver and muscle, in normal and type 2 diabetic state. Regul. Pept. 153, 88-92 (2009).
35. Green, B. D. et al. GLP 1 and related peptides cause concentration- dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch. Biochem. Biophys. 478, 136-142 (2008).
36. Bjerre Knudsen, L. et al. Glucagon-like Peptide 1 receptor agonists activate rodent thyroid C cells causing calcitonin release and C cell proliferation. Endocrinology 151, 1473-1486 (2010).
37. FDA Briefing Materials Table of Contents-Liraglutide. FDA Website [online] http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4422b2-01-FDA.pdf (2011).
38. Hegedüs, L., Moses, AC, Zdravkovic, M, Le Thi, T. & Daniels, GH. GLP 1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5,000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP 1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96, 853-860 (2011).
39. Nystrom, T. et al. Effects of glucagon-like peptide 1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287, E1209 E1215 (2004). (Pubitemid 39491964)
40. Sonne, D. P., Engstrom, T. & Treiman, M. Protective effects of GLP 1 analogs exendin 4 and GLP 1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 146, 243-249 (2008).
41. Gaede, P. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003). (Pubitemid 36159355)
42. Jurado, J. et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J. Am. Acad. Nurse. Pract. 21, 140-148 (2009).
43. Suwaidi, J. A. et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101, 948-954 (2000). (Pubitemid 30131694)
44. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703-713 (1998).
45. Gutzwiller, J. P. et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J. Clin. Endocrinol. Metab. 89, 3055-3061 (2004).
46. Astrup, A. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP 1 analog, liraglutide. Int. J. Obes. (Lond) http://dx.doi.org/10.1038/ijo.2011.158.
47. Basu, A. et al. Beneficial effects of GLP 1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am. J. Physiol. Endocrinol. Metab. 293, E1289-E1295 (2007). (Pubitemid 350106596)
48. Golpon, H. A., Puechner, A., Welte, T., Wichert, P. V. & Feddersen, C. O. Vasorelaxant effect of glucagon-like peptide (7-36)amide and amylin on the pulmonary circulation of the rat. Regul. Pept. 102, 81-86 (2001). (Pubitemid 33135568)
49. Nystrom, T., Gonon, A. T., Sjoholm, A. & Pernow, J. Glucagon-like peptide 1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul. Pept. 125, 173-177 (2005). (Pubitemid 39593722)
50. Ozyazgan, S., Kutluata, N., Afsar, S., Ozdas, S. B. & Akkan, A. G. Effect of glucagon-like peptide 1(7-36) and exendin 4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats. Pharmacology 74, 119-126 (2005). (Pubitemid 40981097)
51. Hansen, L., Hartmann, B., Mineo, H. & Holst, J. J. Glucagon-like peptide 1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum. Regul. Pept. 118, 11-18 (2004). (Pubitemid 38167361)
52. Barragan, J. M., Rodriguez, R. E. & Blazquez, E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide 1 (7-36) amide in rats. Am. J. Physiol. 266, E459-E466 (1994).
53. Barragan, J. M., Rodriguez, R. E., Eng, J. & Blazquez, E. Interactions of exendin (9-39) with the effects of glucagon-like peptide 1 (7-36) amide and of exendin 4 on arterial blood pressure and heart rate in rats. Regul. Pept. 67, 63-68 (1996). (Pubitemid 26384196)
54. Baggio, L. L. & Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132, 2131-2157 (2007). (Pubitemid 46711096)
55. Bucinskaite, V. et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide 1 in the rat. Neurogastroenterol. Motil. 21, 978 e78 (2009).
56. Nishizawa, M. et al. The hepatic vagal reception of intraportal GLP 1 is via receptor different from the pancreatic GLP 1 receptor. J. Auton. Nerv. Syst. 80, 14-21 (2000). (Pubitemid 30160722)
57. Barragan, J. M., Eng, J., Rodriguez, R. & Blazquez, E. Neural contribution to the effect of glucagon-like peptide 1 (7-36) amide on arterial blood pressure in rats. Am. J. Physiol. 277, E784-E791 (1999).
58. Bojanowska, E. & Stempniak, B. Effects of centrally or systemically injected glucagon-like peptide 1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul. Pept. 91, 75-81 (2000).
59. Isbil-Buyukcoskun, N. & Gulec, G. Effects of intracerebroventricularly injected glucagon-like peptide 1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul. Pept. 118, 33-38 (2004). (Pubitemid 38167364)
60. Yamamoto, H. et al. Glucagon-like peptide 1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J. Clin. Invest. 110, 43-52 (2002). (Pubitemid 34743464)
61. Yu, M. et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J. Hypertens. 21, 1125-1135 (2003). (Pubitemid 36667866)
62. Moreno, C., Mistry, M. & Roman, R. J. Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol. 434, 163-167 (2002). (Pubitemid 34056575)
63. Toft-Nielsen, M. B., Madsbad, S. & Holst, J. J. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137-1143 (1999). (Pubitemid 29293967)
64. Halbirk, M. et al. Cardiovascular and metabolic effects of 48 h glucagon-like peptide 1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 298, H1096-H1102 (2010).
65. Gutzwiller, J. P. et al. Glucagon-like peptide 1 is involved in sodium and water homeostasis in humans. Digestion 73, 142-150 (2006).
66. Okerson, T., Yan, P., Stonehouse, A. & Brodows, R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am. J. Hypertens. 23, 334-339 (2010).
67. Bergenstal, R. M. et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION 2): a randomised trial. Lancet 376, 431-439 (2010).
68. Diamant, M. et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION 3): an open-label randomised trial. Lancet 375, 2234-2243 (2010).
69. Drucker, D. J. et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372, 1240-1250 (2008).
70. Buse, J. B. et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD 6). Lancet 374, 39-47 (2009).
71. Garber, A. et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD 3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373, 473-481 (2009).
72. Marre, M. et al. Liraglutide, a once-daily human GLP 1 analog, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD 1 SU). Diabet. Med. 26, 268-278 (2009).
73. Nauck, M. et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes) 2 study. Diabetes Care 32, 84-90 (2009).
74. Russell-Jones, D. et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD 5 met+SU): arandomised controlled trial. Diabetologia 52, 2046-2055 (2009).
75. Zinman, B. et al. Efficacy and safety of the human glucagon-like peptide 1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD 4 Met+TZD). Diabetes Care 32, 1224-1230 (2009).
76. Diaz, A., Bourassa, M. G., Guertin, M. C. & Tardif, J. C. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur. Heart J. 26, 967-974 (2005). (Pubitemid 40695027)
77. Jensen, M. T., Marott, J. L., Allin, K. H., Nordestgaard, B. G. & Jensen, G. B. Resting heart rate is associated with cardiovascular and all-cause mortality after adjusting for inflammatory markers: The Copenhagen City Heart Study. Eur. J. Cardiovasc. Prev. Rehabil. http://dx.doi.org/10.1177/ 1741826710394274.
78. Jouven, X. et al. Heart-rate profile during exercise as a predictor of sudden death. N. Engl. J. Med. 352, 1951-1958 (2005). (Pubitemid 40638365)
79. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
80. Hattori, Y. et al. A glucagon-like peptide 1 (GLP 1) analog, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 53, 2256-2263 (2010).
81. Arakawa, M. et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide 1 receptor agonist, exendin 4. Diabetes 59, 1030-1037 (2010).
82. Hirano, T. et al. Incretins directly suppress the development of macrophage-driven atherosclerosis in apolipoprotein E null mice. Diabetologia 53(Supl. 1), S72 (2010).
83. Nagashima, M. et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia 54, 2649-2659 (2011).
84. Liu, H., Dear, A. E., Knudsen, L. B. & Simpson, R. W. A long-acting glucagon-like peptide 1 analog attenuates induction of plasminogen activator inhibitor type 1 and vascular adhesion molecules. J. Endocrinol. 201, 59-66 (2009).
85. Plutzky, J., Garber, A., Falahati, A., Toft, A. D. & Poulter, N. R. The once-daily human GLP-1 analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials [abstract]. Eur. Heart J. 30 (Suppl. 1), 917 (2009).
86. Viswanathan, P. et al. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr. Pract. 13, 444-450 (2007).
87. Courreges, J. P. et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide 1 analog, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet. Med. 25, 1129-1131 (2008).
88. Bunck, M. C. et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 33, 1734-1737 (2010).
89. Diamant, M. et al. Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk f actors in subjects with type 2 diabetes [abstract]. Diabetologia 53 (Suppl. 1), S344 (2010).
90. Yellon, D. M. & Hausenloy, D. J. Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121-1135 (2007).
91. Bose, A. K., Mocanu, M. M., Carr, R. D. & Yellon, D. M. Glucagon like peptide 1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther. 19, 9-11 (2005). (Pubitemid 40767767)
92. Bose, A. K., Mocanu, M. M., Carr, R. D. & Yellon, D. M. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide 1 (GLP 1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc. Drugs Ther. 21, 253-256 (2007). (Pubitemid 47387464)
93. Ossum, A., van Deurs, U., Engstrom, T., Jensen, J. S. & Treiman, M. The cardioprotective and inotropic components of the postconditioning effects of GLP 1 and GLP 1(9-36)a in an isolated rat heart. Pharmacol. Res. 60, 411-417 (2009).
94. Sager, P. et al. Exenatide once weekly did not affect the QTc interval in patients with type 2 diabetes. Presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
95. Timmers, L. et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53, 501-510 (2009).
96. Kristensen, J. et al. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc. Disord. 9, 31 (2009).
97. Noyan-Ashraf, M. H. et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58, 975-983 (2009).
98. Nikolaidis, L. A. et al. Glucagon-like peptide 1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther. 312, 303-308 (2005). (Pubitemid 40096482)
99. Nikolaidis, LA. et al. Effects of glucagon-like peptide 1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109, 962-965 (2004). (Pubitemid 38282847)
100. Read, P. A. et al. A pilot study to assess whether glucagon-like peptide 1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv. 4, 266-272 (2011).
101. Lønborg, J. et al. Exenatide reduces reperfusion injury in patients with ST segment elevation myocardial infarction. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehr309.
102. Ravassa, S., Zudaire, A., Carr, R. D. & Diez, J. Antiapoptotic effects of GLP 1 in murine HL 1 cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 300, H1361-H1372 (2011).
103. Kavianipour, M. et al. Glucagon-like peptide 1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 24, 569-578 (2003). (Pubitemid 36829346)
104. Vila Petroff, M. G., Egan, J. M., Wang, X. & Sollott, S. J. Glucagon-like peptide 1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ. Res. 89, 445-452 (2001). (Pubitemid 34132661)
105. Bhashyam, S. et al. Glucagon-like peptide 1 increases myocardial glucose uptake via p38alpha MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ. Heart Fail. 3, 512-521 (2010).
106. Nikolaidis, L. A. et al. Recombinant glucagon-like peptide 1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110, 955-961 (2004). (Pubitemid 39128621)
107. Nikolaidis, L. A., Elahi, D., Shen, Y. T. & Shannon, R. P. Active metabolite of GLP 1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 289, H2401-H2408 (2005). (Pubitemid 41698549)
108. Zhao, T. et al. Direct effects of glucagon-like peptide 1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther. 317, 1106-1113 (2006). (Pubitemid 43764114)
109. Nguyen, T. D. Oleate controls the effects of GLP 1 and exendin 4 on myocardial glucose utilization and contractile function [abstract]. Eur. Heart J. 37 (Suppl. 1), 937 (2010).
110. Nathanson, D. et al. Plasma levels of glucagon like peptide 1 associate with diastolic function in elderly men. Diabet. Med. 28, 301-305 (2011).
111. Sokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D. & Shannon, R. P. Glucagon-like peptide 1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail. 12, 694-699 (2006). (Pubitemid 44881367)
112. Mussig, K. et al. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am. J. Cardiol. 102, 646-647 (2008).
113. Heller, S. R. Abnormalities of the electrocardiogram during hypoglycemia: the cause of the dead in bed syndrome? Int. J. Clin. Pract. Suppl. 129, 27-32 (2002).
114. Linnebjerg, H. et al. A thorough QT study to evaluate the effects of singledose exenatide 10 mug on cardiac repolarization in healthy subjects. Int. J. Clin. Pharmacol. Ther. 49, 594-604 (2011).
115. Chatterjee, D. J., Khutoryansky, N., Zdravkovic, M., Sprenger, C. R. & Litwin, J. S. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP 1 analog for treatment of type 2 diabetes. J. Clin. Pharmacol. 49, 1353-1362 (2009).
116. Sokos, G. G. et al. Effect of glucagon-like peptide 1 (GLP 1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. 100, 824-829 (2007). (Pubitemid 47268274)
117. Williamson, D. F. et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23, 1499-1504 (2000).
118. Klonoff, D. C. et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286 (2008). (Pubitemid 351160260)
119. Moretto, T. J. et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 30, 1448-1460 (2008).
120. Jendle, J. et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide 1 analog for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes. Metab. 11, 1163-1172 (2009).
121. Hsieh, J. et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53, 552-561 (2010).
122. Schwartz, E. A. et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 212, 217-222 (2010).
123. Dokken, B. B. et al. Glucagon-like peptide 1 (GLP 1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 81, 755-760 (2010).
124. Ku, H. C., Chen, W. P. & Su, M. J. GLP 1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn-Schmiedebergs Archives of Pharmacology 382, 463-474 (2010).
125. Nissen, S. E. & Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356, 2457-2471 (2007). (Pubitemid 46919772)
126. Rao, A. D., Kuhadiya, N., Reynolds, K. & Fonseca, V. A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31, 1672-1678 (2008).
127. Yudkin, J. S., Lehman, R. & Krumholz, H. M. Glucagon-like peptide 1 drugs. Use of GLP 1 analogs needs great caution. BMJ 342, d1478 (2011).
128. Best, J. H. et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP 1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34, 90-95 (2011).
129. Blevins, T. et al. DURATION 5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 1301-1310 (2011).
130. Buse, J. B. et al. Effects of exenatide (exendin 4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27, 2628-2635 (2004). (Pubitemid 39441462)
131. DeFronzo, R. A. et al. Effects of exenatide (exendin 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28, 1092-1100 (2005). (Pubitemid 40616618)
132. Kendall, D. M. et al. Effects of exenatide (exendin 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28, 1083-1091 (2005). (Pubitemid 40616617)
133. Barakat, G. M. et al. Role of glucagon-like peptide 1 and its agonists on early prevention of cardiac remodeling in type 1 diabetic rat hearts. Gen. Physiol. Biophys. 30, 34-44 (2011).
134. Nakagawa, A. et al. Receptor gene expression of glucagon-like peptide 1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton. Neurosci. 110, 36-43 (2004). (Pubitemid 38180536)
135. Delgado, E. et al. Glucagon-like peptide 1 binding to rat skeletal muscle. Peptides 16, 225-229 (1995).